Voya Investment Management LLC Increases Holdings in Apellis Pharmaceuticals, Inc. $APLS

Voya Investment Management LLC increased its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 14.8% during the third quarter, according to its most recent filing with the SEC. The fund owned 172,934 shares of the company’s stock after buying an additional 22,341 shares during the quarter. Voya Investment Management LLC owned 0.14% of Apellis Pharmaceuticals worth $3,913,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its position in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock worth $33,000 after acquiring an additional 855 shares during the period. Osaic Holdings Inc. increased its stake in shares of Apellis Pharmaceuticals by 141.2% during the 2nd quarter. Osaic Holdings Inc. now owns 2,682 shares of the company’s stock worth $47,000 after purchasing an additional 1,570 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Apellis Pharmaceuticals by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,855 shares of the company’s stock worth $84,000 after purchasing an additional 655 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 338.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 5,429 shares of the company’s stock worth $94,000 after purchasing an additional 4,191 shares during the period. Finally, Headlands Technologies LLC lifted its stake in Apellis Pharmaceuticals by 748.8% in the second quarter. Headlands Technologies LLC now owns 6,892 shares of the company’s stock valued at $119,000 after purchasing an additional 6,080 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling

In other news, CFO Timothy Eugene Sullivan sold 10,000 shares of the company’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief financial officer owned 110,936 shares of the company’s stock, valued at approximately $3,109,536.08. This represents a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director A. Sinclair Dunlop sold 31,092 shares of the stock in a transaction on Friday, October 10th. The stock was sold at an average price of $23.72, for a total value of $737,502.24. Following the completion of the sale, the director owned 3,837 shares in the company, valued at $91,013.64. This trade represents a 89.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 56,092 shares of company stock valued at $1,366,652. Company insiders own 6.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on APLS shares. Mizuho decreased their target price on Apellis Pharmaceuticals from $24.00 to $19.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. TD Cowen decreased their price objective on Apellis Pharmaceuticals from $50.00 to $45.00 and set a “buy” rating for the company in a report on Friday, October 31st. Wall Street Zen raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Wells Fargo & Company started coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 15th. They issued an “overweight” rating and a $32.00 target price for the company. Finally, The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and lowered their price target for the company from $26.00 to $18.00 in a research report on Friday, September 26th. Eleven investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $33.94.

Apellis Pharmaceuticals Stock Down 0.8%

APLS stock opened at $24.97 on Friday. The company has a quick ratio of 3.10, a current ratio of 3.54 and a debt-to-equity ratio of 0.90. The firm has a market capitalization of $3.16 billion, a PE ratio of 80.55 and a beta of 0.37. Apellis Pharmaceuticals, Inc. has a twelve month low of $16.10 and a twelve month high of $35.57. The stock has a 50-day simple moving average of $23.13 and a two-hundred day simple moving average of $22.81.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Thursday, October 30th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million for the quarter, compared to the consensus estimate of $364.58 million. During the same period in the prior year, the firm posted ($0.46) earnings per share. The company’s revenue for the quarter was up 133.0% on a year-over-year basis. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company’s research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.

The company’s lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.